Search results (708)
« Back to PublicationsBimekizumab treatment in patients with active psoriatic arthritis and prior inadequate response to tumour necrosis factor inhibitors: 52-week safety and efficacy from the phase III BE COMPLETE study and its open-label extension BE VITAL
Journal article
Coates LC. et al, (2026), RMD Open, 20, e043855 - e043855
Effects of Guselkumab on Structural Damage Progression in Patients with Active Psoriatic Arthritis
Journal article
Ritchlin CT. et al, (2026), Advances in Therapy
State of the art and novel treatments in psoriatic arthritis.
Journal article
Hackett S. et al, (2026), Best Pract Res Clin Rheumatol
Further Validation of a Questionnaire to Assess Flare in Psoriatic Arthritis: Determination of Cutoff and Longitudinal Change.
Journal article
Helliwell PS. et al, (2026), J Rheumatol
Ixekizumab With Tirzepatide Achieved Greater Disease Control Than Ixekizumab Alone in Adults With Psoriatic Arthritis and Overweight or Obesity: Results From a Randomized Clinical Trial.
Journal article
Merola JF. et al, (2026), Arthritis Rheumatol
Cohort Study on Drug Survival and Tolerability of Adalimumab Biosimilar Transitioning: Pharmaceutical Properties Do Matter.
Journal article
Peeters ACD. et al, (2026), Clin Pharmacol Ther, 119, 651 - 659
Frequency and Characteristics of Axial Involvement in Psoriatic Arthritis: Results from the International Multicentre AXIS Study.
Journal article
Coates L. and Torgutalp M., (2026), Annals of the Rheumatic Diseases
“I am struggling to find an explicit task”—a midterm evaluation of patient research partner involvement in HIPPOCRATES translational research
Journal article
de Wit M. et al, (2026), EULAR Rheumatology Open, 100157 - 100157
Composite and pragmatic measures in psoriatic arthritis: bridging trials and clinical feasibility.
Journal article
Kang J-H. and Coates LC., (2026), Curr Opin Immunol, 99
Bimekizumab safety and efficacy in patients with psoriatic arthritis: 3-year results from two phase 3 studies
Journal article
Gossec L. et al, (2026), Rheumatology
Comparative effectiveness and persistence of ixekizumab and other b/tsDMARDs in patients with PsA from a real-world setting: 12-month results from the PRO-SPIRIT study.
Journal article
Marzo-Ortega H. et al, (2026), RMD Open, 12
Therapeutic Windows Across the Psoriatic Arthritis Spectrum.
Journal article
Kang J-H. and Coates LC., (2026), Rheumatol Ther, 13, 27 - 43
Influence of Biological Sex on Participant Characteristics, Guselkumab Efficacy and Radiographic Progression in Active Psoriatic Arthritis: Post Hoc Analysis of Three Randomized Trials.
Journal article
Gladman DD. et al, (2026), Rheumatol Ther, 13, 213 - 229
Comment on: Key factors contributing to gender inequity in global rheumatology awards: a global survey analysis: Reply.
Journal article
Minikumari Rahulan L. et al, (2026), Rheumatology (Oxford)
Trialblazers: patient-driven redesign of a clinical trial in psoriatic arthritis.
Journal article
Struthers C. et al, (2026), Lancet Rheumatol